Á lódáil...
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM) patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in MYD88-mutated (MYD88(MUT)) WM patients, but shows lower activity in MYD88 wild-type (MYD88(WT)) disease. MYD88(WT) patients a...
Na minha lista:
| Foilsithe in: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
American Society of Hematology
2018
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6234368/ https://ncbi.nlm.nih.gov/pubmed/30401751 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018022962 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|